NASDAQ:NERV

Minerva Neurosciences (NERV) Stock Forecast, Price & News

$6.97

+0.07 (+1.01%)

(As of 09:30 AM ET)

Compare

Today's Range: $6.97
▼
$6.97
50-Day Range: $6.90
▼
$10.52
52-Week Range: $1.26
▼
$14.70

Volume: 620 shs
Average Volume: 401,982 shs
Market Capitalization: $48.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Minerva Neurosciences MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 59.4% Upside
$11.00 Price Target
Short Interest: Healthy
1.53% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.89
Upright™ Environmental Score
News Sentiment: 0.63
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.94) to ($3.44) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

315th out of 969 stocks

Pharmaceutical Preparations Industry

129th out of 454 stocks

3.0

Analyst's Opinion

Consensus Rating
Minerva Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, Minerva Neurosciences has a forecasted upside of 59.4% from its current price of $6.90.
Amount of Analyst Coverage
Minerva Neurosciences has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.53% of the float of Minerva Neurosciences has been sold short.
Short Interest Ratio / Days to Cover
Minerva Neurosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Minerva Neurosciences has recently decreased by 7.85%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Minerva Neurosciences does not currently pay a dividend.
Dividend Growth
Minerva Neurosciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Minerva Neurosciences has received a 71.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for Parkinsonism", "Clinical research services for schizophrenia", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Minerva Neurosciences is -0.89.

2.6

News and Social Media Coverage

News Sentiment
Minerva Neurosciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Minerva Neurosciences this week, compared to 1 article on an average week.
MarketBeat Follows
3 people have added Minerva Neurosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.40% of the stock of Minerva Neurosciences is held by insiders.
Percentage Held by Institutions
55.11% of the stock of Minerva Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Minerva Neurosciences are expected to grow in the coming year, from ($3.94) to ($3.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Minerva Neurosciences is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Minerva Neurosciences is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Minerva Neurosciences (NASDAQ:NERV) Stock

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

NERV Price History

30 days | 90 days | 365 days | Advanced Chart

NERV Stock News Headlines

September 28, 2023 | americanbankingnews.com

Contrasting Minerva Neurosciences (NASDAQ:NERV) and Atossa Therapeutics (NASDAQ:ATOS)

August 23, 2023 | msn.com

Minerva Neurosciences: There's Probably Time For One More Rally

October 2, 2023 | PressReach (Ad)

Nuclear Revival Creates Opportunities for Uranium

Uranium companies set to benefit from increased demand for clean energy.

August 1, 2023 | finance.yahoo.com

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

June 28, 2023 | finanznachrichten.de

Minerva Neurosciences, Inc: Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

June 28, 2023 | benzinga.com

Minerva Neurosciences shares are trading higher after the company announced a $20 million private placement priced at a premium to the market.

June 28, 2023 | marketwatch.com

Minerva Neurosciences Shares Jump Premarket After Private Placement

June 28, 2023 | msn.com

Why Minerva Neurosciences Stock Is Shooting Higher Today

October 2, 2023 | PressReach (Ad)

Nuclear Revival Creates Opportunities for Uranium

Uranium companies set to benefit from increased demand for clean energy.

June 28, 2023 | finance.yahoo.com

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

June 9, 2023 | finance.yahoo.com

Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now

May 19, 2023 | msn.com

Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead

May 18, 2023 | finance.yahoo.com

What Makes Minerva Neurosciences (NERV) a New Buy Stock

May 15, 2023 | benzinga.com

Minerva Neurosciences Q1 2023 R&D Expenses $2.7M Vs $5M YoY

May 15, 2023 | finance.yahoo.com

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

May 15, 2023 | msn.com

Minerva Neurosciences GAAP EPS of -$1.31

May 15, 2023 | finance.yahoo.com

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

May 10, 2023 | marketwatch.com

Minerva Neurosciences Gets FDA Confirmation for NDA for Roluperidone

May 8, 2023 | finance.yahoo.com

Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

May 3, 2023 | benzinga.com

Minerva Neurosciences Stock (NASDAQ:NERV), Guidance and Forecast

May 3, 2023 | benzinga.com

Minerva Neurosciences Stock (NASDAQ:NERV), Short Interest Report

May 2, 2023 | markets.businessinsider.com

Minerva Neurosciences (NERV) Receives a Hold from H.C. Wainwright

May 1, 2023 | marketwatch.com

Minerva Neurosciences Shares Rise 25% FDA Files NDA for Roluperidone

May 1, 2023 | finance.yahoo.com

Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

April 27, 2023 | marketwatch.com

Insomnia Medication Market Forecast to 2030

March 10, 2023 | finance.yahoo.com

Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call Transcript

March 9, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Minerva Neurosciences (NERV) and Evolus (EOLS)

See More Headlines

Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

NERV Company Calendar

Last Earnings: 8/01/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NERV
CUSIP: N/A
CIK: 1598646
Web: www.minervaneurosciences.com
Phone: (617) 600-7373
Fax: N/A
Employees: 9
Year Founded: 2007

Price Target and Rating

Average Stock Price Forecast: $11.00
High Stock Price Forecast: $11.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +59.4%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.98)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-32,110,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -45.87%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 27.37
Quick Ratio: 27.37

Sales & Book Value

Annual Sales: $41.18 million
Price / Sales: 1.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.75) per share
Price / Book: -1.84

Miscellaneous

Outstanding Shares: 6,990,000
Free Float: 6,545,000
Market Cap: $48.23 million
Optionable: Optionable
Beta: 0.25

Social Links

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Remy Luthringer Ph.D. (Age 62)
Exec. Chairman & CEO
Comp: $853.58k

Mr. Geoffrey Robin Race F.C.M.A. (Age 62)
FCMA, M.B.A., MBA, Pres
Comp: $628.46k

Mr. Frederick W. Ahlholm CPA (Age 57)
CPA, Sr. VP, CFO & Sec.
Comp: $567.49k

Mr. Joseph Reilly (Age 48)
Sr. VP & COO

Mr. William B. Boni (Age 71)
VP of Investor Relations & Corp. Communications

Prof. Michael Davidson M.D. (Age 73)
Chief Medical Officer

Dr. Ramana Kuchibhatla Ph.D.
Sr. VP and Head of R&D

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NERV Stock - Frequently Asked Questions

Should I buy or sell Minerva Neurosciences stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NERV, but not buy additional shares or sell existing shares.
View NERV analyst ratings or view top-rated stocks.
What is Minerva Neurosciences' stock price forecast for 2023?: 2 equities research analysts have issued 12 month price targets for Minerva Neurosciences' shares. Their NERV share price forecasts range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 59.4% from the stock's current price.
View analysts price targets for NERV or view top-rated stocks among Wall Street analysts.
How have NERV shares performed in 2023?: Minerva Neurosciences' stock was trading at $1.59 at the beginning of the year. Since then, NERV stock has increased by 334.0% and is now trading at $6.90.
View the best growth stocks for 2023 here.
When is Minerva Neurosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our NERV earnings forecast.
How were Minerva Neurosciences' earnings last quarter?: Minerva Neurosciences, Inc. (NASDAQ:NERV) issued its quarterly earnings results on Tuesday, August, 1st. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.68.
When did Minerva Neurosciences' stock split?: Minerva Neurosciences shares reverse split on the morning of Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Minerva Neurosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).
What is Minerva Neurosciences' stock symbol?: Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."
How do I buy shares of Minerva Neurosciences?: Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Minerva Neurosciences' stock price today?: One share of NERV stock can currently be purchased for approximately $6.90.
How much money does Minerva Neurosciences make?: Minerva Neurosciences (NASDAQ:NERV) has a market capitalization of $48.23 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $-32,110,000.00 in net income (profit) each year or ($4.98) on an earnings per share basis.
How can I contact Minerva Neurosciences?: Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The official website for the company is www.minervaneurosciences.com. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at wboni@minervaneurosciences.com.

This page (NASDAQ:NERV) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial